1st Order Pharmaceuticals (1OP) is a privately held, early development-stage pharmaceutical company focused on advancing 1OP-2198, an IND-ready small molecule potassium channel opener, for unmet medical and orphan indications in neurology and neuro-ophthalmology. We use accepted scientific principles in pharmacokinetic and pharmacodynamic (PK/PD) modeling to enable intelligent drug development strategies on validated targets coupled with rational development strategies that allow for innovation within follow-on indications. 1OP has a clear development path for each of the indications and has a strong strategy on expanding the patent portfolio around 1OP-2198 and ring fencing the therapeutic indications with a unique formulation strategy. Our technology, experience in the scientific space, defendable intellectual property and formulation plan creates a compelling value proposition. Learn more at www.1storderpharma.com.